Literature DB >> 17761832

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

Xavier Leleu1, Xiaoying Jia, Judith Runnels, Hai T Ngo, Anne-Sophie Moreau, Mena Farag, Joel A Spencer, Costas M Pitsillides, Evdoxia Hatjiharissi, Aldo Roccaro, Garrett O'Sullivan, Douglas W McMillin, Daisy Moreno, Tanyel Kiziltepe, Ruben Carrasco, Steven P Treon, Teru Hideshima, Kenneth C Anderson, Charles P Lin, Irene M Ghobrial.   

Abstract

Waldenstrom macroglobulinemia (WM) is an incurable low-grade lymphoplasmacytic lymphoma. We demonstrate up-regulated Akt activity in WM, and that Akt down-regulation by Akt knockdown and the inhibitor perifosine leads to significant inhibition of proliferation and induction of apoptosis in WM cells in vitro, but not in normal donor peripheral blood and hematopoietic progenitors. Importantly, down-regulation of Akt induced cytotoxicity of WM cells in the bone marrow microenvironment (BMM) context. Perifosine induced significant reduction in WM tumor growth in vivo in a subcutaneous xenograft model through inhibition of Akt phosphorylation and downstream targets. We also demonstrated that Akt pathway down-regulation inhibited migration and adhesion in vitro and homing of WM tumor cells to the BMM in vivo. Proteomic analysis identified other signaling pathways modulated by perifosine, such as activation of ERK MAPK pathway, which induces survival of tumor cells. Interestingly, MEK inhibitor significantly enhanced perifosine-induced cytotoxicity in WM cells. Using Akt knockdown experiments and specific Akt and PI3K inhibitors, we demonstrated that ERK activation is through a direct effect, rather than feedback activation, of perifosine upstream ERK pathway. These results provide understanding of biological effects of Akt pathway in WM and provide the framework for clinical evaluation of perifosine in WM patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761832      PMCID: PMC2234792          DOI: 10.1182/blood-2007-05-092098

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Defining Waldenstrom's macroglobulinemia.

Authors:  Steven P Treon; Meletios Dimopoulos; Robert A Kyle
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Morie A Gertz; Athanasios Anagnostopoulos; Kenneth Anderson; Andrew R Branagan; Morton Coleman; Stanley R Frankel; Sergio Giralt; Todd Levine; Nikhil Munshi; Alan Pestronk; Vincent Rajkumar; Steven P Treon
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 3.  Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

Authors:  F Chang; J T Lee; P M Navolanic; L S Steelman; J G Shelton; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

Review 4.  Homing of antibody secreting cells.

Authors:  Jason G Cyster
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

Review 5.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

Review 6.  Waldenström macroglobulinaemia.

Authors:  Irene M Ghobrial; Morie A Gertz; Rafael Fonseca
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

Review 7.  PI3K/Akt signalling pathway and cancer.

Authors:  Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

8.  Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Authors:  Yu-Tzu Tai; Klaus Podar; Laurence Catley; Yu-Hua Tseng; Masaharu Akiyama; Reshma Shringarpure; Renate Burger; Teru Hideshima; Dharminder Chauhan; Nicholas Mitsiades; Paul Richardson; Nikhil C Munshi; C Ronald Kahn; Constantine Mitsiades; Kenneth C Anderson
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

Review 9.  Waldenström macroglobulinemia.

Authors:  Irene M Ghobrial; Thomas E Witzig
Journal:  Curr Treat Options Oncol       Date:  2004-06

Review 10.  Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.

Authors:  Sharon Brader; Suzanne A Eccles
Journal:  Tumori       Date:  2004 Jan-Feb
View more
  62 in total

Review 1.  Utility of mTOR inhibition in hematologic malignancies.

Authors:  Anas Younes; Nousheen Samad
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

Authors:  Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Giulia Perrone; Naoya Miura; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Loredana Santo; Sonia Vallet; Diana Cristea; Elisabetta Calabrese; Gullu Gorgun; Noopur S Raje; Paul Richardson; Nikhil C Munshi; Brian J Lannutti; Kamal D Puri; Neill A Giese; Kenneth C Anderson
Journal:  Blood       Date:  2010-05-26       Impact factor: 22.113

Review 4.  Perifosine: update on a novel Akt inhibitor.

Authors:  Joell J Gills; Phillip A Dennis
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

5.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Authors:  Aldo M Roccaro; Antonio Sacco; Brian Thompson; Xavier Leleu; Abdel Kareem Azab; Feda Azab; Judith Runnels; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Charles P Lin; Domenico Ribatti; Barrett J Rollins; Thomas E Witzig; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

6.  SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.

Authors:  Hai T Ngo; Xavier Leleu; Jack Lee; Xiaoying Jia; Molly Melhem; Judith Runnels; Anne-Sophie Moreau; Nicholas Burwick; Abdel Kareem Azab; Aldo Roccaro; Feda Azab; Antonio Sacco; Mena Farag; Robert Sackstein; Irene M Ghobrial
Journal:  Blood       Date:  2008-04-30       Impact factor: 22.113

7.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

8.  Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Emanuel N Husu; Costas Pitsillides; Steven Vesole; Abdel Kareem Azab; Feda Azab; Molly Melhem; Hai T Ngo; Phong Quang; Patricia Maiso; Judith Runnels; Mei-Chih Liang; Kwok-Kin Wong; Charles Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

9.  Novel agents in Waldenstrom Macroglobulinemia.

Authors:  Antonio Sacco; Xavier Leleu; Giuseppe Rossi; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2010-05-28

10.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

Authors:  Abdel Kareem Azab; Feda Azab; Simona Blotta; Costas M Pitsillides; Brian Thompson; Judith M Runnels; Aldo M Roccaro; Hai T Ngo; Molly R Melhem; Antonio Sacco; Xiaoying Jia; Kenneth C Anderson; Charles P Lin; Barrett J Rollins; Irene M Ghobrial
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.